Topical Negative Pressure (Negative Pressure Wound) Therapy
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs outpatient coverage criteria and clinical guidance for topical negative pressure wound therapy (NPWT) for Blue Cross Blue Shield North Carolina members, including powered, non‑powered, and single‑use systems, and guidance for providers and DME suppliers.
The focus of this document is on use of NPWT in the outpatient setting and recognizes transition from inpatient to outpatient use.
Chronic wounds definition changed from >90 days to >30 days for When Covered criteria.
Clarified criteria for traumatic or large surgical wounds including examples and requirement for exposed bone/cartilage/tendon/fascia or foreign material.
Incisional Negative Pressure Wound Therapy (iNPWT) devices are considered not medically necessary when used over closed surgical wounds.
Contraindications were moved from policy guidelines into the 'When Covered' section; exposed organ is removed as a contraindication.
Coverage Criteria and Clinical Indications
Initial Therapy (Powered NPWT)
Covered when ALL of the following are met:
Initial powered NPWT trial
- Indications: One of: chronic (>30 days) stage III or IV pressure ulcer that failed despite optimal care (with high-volume drainage interfering with healing or standard dressings not maintainable due to anatomy); non‑healing wounds in patients with underlying conditions that impair healing where the wound failed despite ≥30 days of optimal care (examples: diabetes, malnutrition, small vessel disease, morbid obesity); traumatic or large surgical wounds (e.g., laparotomy wounds) where immediate closure is not practical due to size, contamination, and/or location AND there is exposed bone, cartilage, tendon, fascia, or foreign material within the wound AND no contraindications to NPWT; management of fasciotomy wounds for compartment syndrome; open amputation wounds; enterocutaneous fistulas; other listed complex wound scenarios
See policy text for full list of covered indications.
Continuation Therapy (Powered NPWT)
Covered when ALL of the following are met after initial trial:
Objective improvements include development of healthy granulation tissue, progressive wound contracture/decreasing depth, and/or commencement of epithelial spread from wound margins. Ongoing documentation of wound measurements at least biweekly is required.
Non-powered (Mechanical) NPWT
Covered when ALL of the following are met:
AND wound surface area is <100 cm2 and >1 cm2 and <10 cm in widest diameter, AND exudate is not expected to exceed 150 mL total in 3 days. Non‑powered systems are covered only when these additional size and exudate limits are satisfied.
STSG Post-operative NPWT
Covered when ALL of the following are met:
Intended to support graft adherence and graft take as part of routine post‑operative management.
When Covered — Chronic, Acute/Traumatic/Large Surgical Wounds, and Post-STSG
Covered when specific criteria are met for chronic wounds, certain surgical/traumatic wounds, or post‑split‑thickness skin graft care.
Ongoing care requires at least biweekly quantitative wound measurements demonstrating progressive healing.
Policy update clarifies examples and required findings for traumatic/large surgical wounds.
Not Medically Necessary
Therapeutic trials of powered NPWT for other acute or chronic wounds not listed in the When Covered section are not medically necessary. Use of non‑powered NPWT is not medically necessary when size/exudate criteria are not met or when contraindications/active infection/bleeding/exposed tendons are present. Incisional NPWT (iNPWT) devices (e.g., PICO, Prevena) are not medically necessary when used over closed surgical wounds. Coverage beyond four months is generally not medically necessary.
Incisional negative pressure wound therapy (iNPWT) devices are explicitly excluded for use over closed surgical incisions. iNPWT devices (for example, PICO and Prevena) are considered not medically necessary when used over closed surgical wounds. This noncoverage applies to single‑use/portable incision management systems intended to be applied to closed surgical sites rather than open or complex wounds.
NPWT in general is contraindicated for certain wound conditions; examples include necrotic tissue with eschar, untreated osteomyelitis, non‑enteric and unexplored fistulas, malignancy in the wound, exposed nerve, and exposed anastomotic site. These contraindications should be reviewed prior to any NPWT application and are generally applicable to decisions about incisional device use as well.
The policy was updated to make explicit that Incisional Negative Pressure Wound Therapy (iNPWT) systems — examples include the PICO Single Use Negative Pressure Wound Therapy System and the Prevena Incision Management System — are not medically necessary when used over closed surgical wounds. Providers should not expect coverage for these devices when applied to closed incisions.
This statement aligns with the policy’s general exclusion of therapeutic trials of NPWT for wounds not listed in the When Covered section and the broader guidance that NPWT indications and contraindications must be met before coverage is considered.
Therapeutic trials of powered NPWT for acute or chronic wound types that are not specifically listed in the policy’s When Covered section are considered not medically necessary. Initiating NPWT outside the enumerated covered indications is not supported for coverage.
This constraint applies both to initial trials and to treatments proposed for wound types that lack the required documentation of a complete wound therapy program and prior failed conservative management as described elsewhere in the policy.
Continuation of powered NPWT will be considered not medically necessary if the initial 2‑week therapeutic trial or any subsequent treatment period has not produced documented objective improvement in the wound. Objective improvement includes findings such as healthy granulation tissue, progressive wound contracture (decreasing depth or surface area), or the onset of epithelialization.
Operationally, coverage decisions require documentation of serial wound measurements at least biweekly showing progressive healing. If such documentation is absent or if after reasonable treatment duration there is no measurable improvement, the continuation request should be denied as not meeting medical necessity criteria. The policy also notes that coverage beyond four months is generally not medically necessary except in rare, well‑documented circumstances (for example, a very large open sternotomy or abdominal wound).
Billing, Codes, and Device Characteristics
| 97605 | Debridement; open wound, (e.g., fibrin, devitalized tissue), first 20 sq cm or less (added to Billing/Coding section historically) |
| 97606 | Debridement; open wound(s), each additional 20 sq cm, or more (historical) |
| 97607 | Application of wound therapy (added 1/1/2015) |
| 97608 | Removal of NPWT device (added 1/1/2015) |
| A9272 | Disposable NPWT system (specific code added; removed prior note about unlisted code) |
| A7000 | NPWT accessory (historical billing/coding list) |
| A7001 | NPWT accessory (historical) |
| K0743 | Powered NPWT pump (historical) |
| K0744 | Powered NPWT pump (historical) |
| K0745 | NPWT supplies (historical) |
Provider Responsibilities, Prior Authorization, and Documentation
DME processing, supplier credentialing, and benefit verification
Coverage for NPWT components may be processed under Durable Medical Equipment (DME). Verify the member's benefit language and whether prior review is required for rental or purchase. Ensure the DME supplier meets the Plan's eligibility/credentialing requirements before billing or submitting authorization requests.
- Review the individual certificate/member benefit booklet for coverage details and prior review requirements.
- Confirm DME supplier eligibility/credentialing per Plan policy before reimbursement submission.
Prior authorization and coding considerations for NPWT devices and disposables
Document the required initial therapeutic trial and include specific billing/coding for NPWT systems and disposables when requesting coverage or submitting claims.
- Include codes listed in policy as applicable (e.g., 97605–97608, A6550, A7000–A7001, A9272, E2402, K0743–K0746) on submissions where clinically appropriate.
- Provide requested medical record elements (see documentation callouts) to support medical necessity for the initial trial and device/disposable billing.
Initial 2-week powered NPWT therapeutic trial required
Initiate a powered NPWT only after an initial 2-week therapeutic trial as part of a comprehensive wound care program; continuation requires documented objective wound improvement following that trial.
- Therapeutic trial duration: 2 weeks (initial powered NPWT trial).
- Comprehensive wound care program must address factors such as diabetes control, nutrition, pressure relief, and debridement.
Require prior conventional therapy (or documented contraindication) for surgical/traumatic wounds
For surgically created or traumatic wounds, coverage requires documentation that conventional wound therapy was tried and failed or that conventional therapy is contraindicated; NPWT will not be approved as primary treatment in these cases.
- Indication examples include traumatic or large surgical wounds where immediate closure is impractical and there is exposed bone, cartilage, tendon, fascia, or foreign material.
- Operative or wound care notes must document necessity and prior conventional therapy attempts or contraindications.
Medical records commonly requested by BCBSNC
Be prepared to provide medical records when requested; BCBSNC commonly requests specific wound and treatment details to determine medical necessity.
- Type and age of wound and any prior treatment
- Patient compliance with therapies
- Size of wound and amount of drainage
- Comorbid conditions and nutritional status
- Medical records documenting a complete wound therapy program
- Treatment plan with specific functional goals and estimated timelines
- Operative note or wound care notes if request involves surgical/traumatic wounds
Document complete wound therapy program and state necessity in operative/wound care notes
Medical records must document a complete wound therapy program and clearly state the medical necessity for NPWT; for surgical/traumatic wounds the operative note or wound care notes must explicitly justify use of NPWT.
- A complete wound therapy program should be documented in the medical records (see Policy Guidelines for required elements).
- Necessity for NPWT in surgical/traumatic wounds must be clearly stated in the operative note or wound care records.
Treatment plan must state goals, timeline, and document objective improvement
Include a treatment plan that states specific functional goals, estimates when those goals will be reached, and documents objective improvement after the initial therapeutic trial.
- Document objective improvements such as healthy granulation tissue, progressive wound contracture/decreasing depth, and commencement of epithelialization.
- Maintain biweekly quantitative wound measurements (length, width/surface area, depth) showing progressive healing during ongoing care.
Denial triggers for continuation of powered NPWT
Continuation will be denied if the initial 2-week trial or subsequent treatment period has not produced documented objective improvement, if the wound develops complications that contraindicate NPWT, or if the wound has healed sufficiently for grafting or expected complete healing with other treatments.
- Lack of documented objective improvement after the therapeutic trial is a trigger for denial.
- Development of wound complications that contraindicate continued NPWT (per policy contraindications) is a trigger for denial.
- If the wound has healed to an extent that grafting can be performed or complete healing is expected with other treatments, continuation is not medically necessary.
Additional denial and coverage risk conditions (missing program documentation, time limits)
Coverage may be denied if records do not show a complete wound therapy program was tried and failed (when required), if the initial trial lacks objective improvement documentation, or if use extends beyond durations generally considered not medically necessary (e.g., beyond four months).
- Ensure documentation shows a complete wound therapy program attempt and failure for chronic or surgically created/traumatic wounds when required.
- Avoid using NPWT beyond four months without clear documentation of continued medical necessity; coverage beyond four months is generally not medically necessary.
Definitions and Device Types
Background and Evidence Overview
Topical negative pressure wound therapy (NPWT) applies controlled subatmospheric pressure to a wound bed through a sealed dressing connected to a device that removes exudate. The intended therapeutic effects include removal of excess wound fluid and debris, reduction of interstitial edema, promotion of granulation tissue formation, and optimization of the wound environment to support re‑epithelialization or preparation for grafting or flap coverage.
NPWT can be used as an adjunct to comprehensive wound care when conventional measures (such as debridement, infection control, pressure off‑loading, and optimize medical comorbidities and nutrition) are insufficient. Devices range from powered pump systems to portable single‑use and non‑powered mechanical systems; this policy focuses on outpatient use while recognizing that some individuals may initiate therapy in the inpatient setting and then transition to outpatient care.
The policy guidelines were updated to reflect the available evidence and policy interpretation for portable single‑use NPWT devices, including PICO and the Prevena incision management system. The policy now explicitly reviews evidence for these single‑use systems and clarifies coverage stance: portable single‑use devices intended for open complex wounds may be considered under the When Covered criteria, whereas incisional use over closed surgical wounds is not covered (see the explicit iNPWT exclusion).
Evidence considerations informed other 2025 changes: the chronic wound threshold for coverage was revised to >30 days (previously >90 days), additional specificity was added for traumatic/large surgical wounds (requirements such as exposed bone/cartilage/tendon/fascia or foreign material), and contraindications were reorganized into the When Covered criteria. Providers should review the policy’s When Covered and documentation requirements when assessing single‑use NPWT devices for outpatient coverage.
Policy Revision History
Policy retitled to 'Topical Negative Pressure Therapy for Wounds'; chronic wound threshold changed from >90 days to >30 days; clarified traumatic/large surgical wound criteria and moved some contraindications into 'When Covered'; added explicit noncoverage statement for incisional NPWT (e.g., PICO, Prevena); description language clarified to note inpatient-to-outpatient transition recognition.
Notification issued for the policy changes and effective date of 2025-07-16; Specialty Matched Consultant Advisory Panel and Medical Director reviews completed in April 2025.
References updated and policy guidelines revised following Specialty Matched Consultant Advisory Panel and Medical Director reviews in April 2026.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.